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Narcolepsy is a chronic neurological disease characterized by diurnal excessive sleepiness and
catapleaxy. It affects 1 in every 2000 to 4000 individuals with personal, social and familiar
signiﬁcant repercussions. The treatment of narcolepsy is mainly based on the use of stimulants
for the control of the diurnal excessive sleepiness, in conjunction with behavioral measures and
sleep hygiene. Among the stimulants, modaﬁnil has presently been the drug of choice for the
treatment of the diurnal excessive sleepiness in patients with narcolepsy. In the worldwide
experience, its use is better tolerated and the majority of its side effects is considered light or
moderate. However, the clinical use in Brazil was initiated at the end of 2008, with little
experience on the narcolepsy population of this country. In this context, the objective of this
study was the evaluation of the use of modaﬁnil, verifying the indication of use, causes for
discontinuation, daily dosage, efﬁciency of the treatment in a patient sample of narcoleptics
consulted in a specialized center in Brazil. In this study, modaﬁnil was effective for the control
of the symptoms related do narcolepsy in 66% of the studied patients. The side effects such as
headache, parestesias and diarrhea were the main reasons for the discontinuation of treatment
with modaﬁnil. It is important to clinically follow up the patients for a long period to evaluate
symptomatology, control of use, tolerability and re-evaluation of the more effective therapeutic
dosage able to control narcolepsy. Due to its high cost and clinical beneﬁts, this drug should be
on the government's list of free drugs for the treatment of these patients.
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Narcolepsy is a chronic neurological disease characterized by
diurnal excessive sleepiness (DES), sleep paralysis, hypnago-
gic or hypnopompic hallucinations and cataplexy [1]. Narco-
lepsy with cataplexy represents about 60–70% of all attended
cases in treatment centers for these patients [2,3]. Actually,
we know that narcolepsy with cataplexy and the deﬁciency of
hypocretin are associated with polymorphism of the human
leukocyte antigen HLA-DQB1n0602, altered levels of CD40L
and T cell receptors, suggesting that an autoimmune process
might be involved [3].
Narcolepsy affects 1 in every 2000–4000 individuals in the
general population and the treatment aims to control the
diurnal excessive sleepiness (DES), nocturnal complaints of
sleep fragmentation, cataplexy and psychosocial adaptation
[4,5]. DES is treated with sleep hygiene measures, programmed
naps and social measures (working time adaptation to accom-
modate for naps). Stimulant medications are also utilized to
increase awareness, such as modaﬁnil and methylfenidate [2].
For the control of cataplexy, tricyclic antidepressants can be
used, serotonin-reuptake inhibitor antidepressants and dual
antidepressants, besides some other drugs such as sodium
hydroxybutyrate (not available in Brazil) [4].
Modaﬁnil is a non-amphetamine stimulant that promotes
the vigil state, whose mechanism of action is still not fully
understood. However, it has been demonstrated that mod-
aﬁnil acts via the blockage of dopamine transporter (DAT)
and also the noradrenalin transporter (NET). Besides having
these adrenergic effects, modaﬁnil also acts as agonist of the
hypocretin-1 system, something not detected among
the traditional stimulants. Modaﬁnil has been utilized as
the treatment of choice for DES because it acts over more
speciﬁc brain areas such as the anterior and lateral region of
the hypothalamus and for demonstrating much less side
effects, such as addiction and cardiovascular disorders [4,6].
Its clinical use was initiated more consistently in Brazil at the
end of 2008, after the approval of its normal commercialization
by the National Sanitary Vigilance Agency (ANVISA). For this
reason, there is very little experience of the use of modaﬁnil for
the control of narcolepsy in the population with narcolepsy in
Brazil. In this sense and considering the need for a larger view of
the use of modaﬁnil in the abovementioned population, the
objective of this study was the evaluation of modaﬁnil in the
treatment of diurnal excessive sleepiness in a population of
patients with narcolepsy attended by a Sleep Center in the
country.2. Methods
This study is a retrospective study and was approved by the
Ethical Committee of Research of the Federal University of São
Paulo (1802/07). Hundred and twenty two patient ﬁles of patients
with diagnosis of narcolepsy with regular follow up by the
outpatient facility of Diurnal Excessive Sleepiness of the Federal
University of São Paulo were analyzed. The clinical and electro-
physiological criteria for the diagnosis of narcolepsy follow the
American Academy of Sleep Medicine's criteria [1]. Inclusioncriteria were patients with narcolepsy with regular follow up by
the unit and with ﬁles that had complete and legible informa-
tion. Exclusion criteria included patients already medicated with
modaﬁnil before the ﬁrst consultation, with history of allergy to
the drug or that had no ﬁnancial condition to buy the
medication.
Modaﬁnil was ﬁrst prescribed at the Outpatient Facility of
Excessive Sleepiness for the narcolepsy patients in 20/03/
2008. The inicital standard dose was 100 mg per day, with
progressive increase of 100 mg every return, under clinical
scrutiny. The criterion parameter used for the control of DES
was subjective and it was for the improvement of the
Epworth Sleepiness Scale (ESS) scores. However, the ﬁles did
not contained all noted information referring to the ESS
scores for every return, which did not make it possible for
the clinical team to use them as parameters.3. Results
Of the 122 patients, 11 patients (9,1%) utilized modaﬁnil as a
single drug, 60 (49,2%) patients were treated with methylfe-
nidate and 51 patients (41,7%) used modaﬁnil in association
with other drugs such as Ritalin, tricyclic antidepressants,
serotonin-reuptake inhibitors, anticonvulsants, serotonin
and noradrenalin-reuptake inhibitors (Table 1).
Among the main reasons for discontinuation of modaﬁnil
in 25 patients, we can mention the side effects and poor
clinical improvement (Table 2). Among the side effects, the
major one was headache, comprising about 1/3 of the
patients using modaﬁnil (Table 3).
The most prescribed modaﬁnil dose for the control of DES
was 200 mg daily. This dose was used in 45.3% of the cases of
narcolepsy treated with modaﬁnil. However, in 4 cases, there
was the need to increase the dosage above 200 mg for the
control of the clinical symptoms.4. Discussion
In worldly experience, the use of modaﬁnil is reported as
being well tolerated by the patients with narcolepsy and the
majority of side effects is considered light or moderate [6].
This study demonstrates the use and safety of this drug for
the treatment of DES in our population of narcoleptics.
However, the difﬁculties to access the medication due to its
high cost and the lack of public availability through our
national health system creates severe barriers for its regular
use for the majority of our population.
Among the side effects, the most common was headache
(10–26%), followed by nervousness or anxiety, nausea, dry
mouth, diarrhea, asthenia and insomnia [6,7]. These side
effects were resolved with the discontinuation of modaﬁnil,
conﬁrming our ﬁndings and showing that the side effects
prevail as limiting factors for the continuity of treatment with
modaﬁnil [6–8]. However, the ﬁnancial limitation of several
patients was, and continue being, a very important and
limiting factor for the continuity of the treatment [8–10].
We know that the cost of modaﬁnil therapy is very
superior of the one with methyphenidate. The treatment
Table 1 – Pharmacological treatment of patients with the diagnosis of narcolepsy.
Last pharmacological treatment in the patient's ﬁle Narcolepsy
with
cataplexy
Narcolepsy
without
cataplexy
Total % % per group of treatment
♀ ♂ ♀ ♂
34 39 27 22 122 100
Modaﬁnil 2 4 5 11 9.01 9.01
ModaﬁnilþRitalin 2 2 4 3.28
ModaﬁnilþRitalinþTricyclic 1 1 2 1.64
ModaﬁnilþRitalinþIRSSa 1 3 2 6 4.92
ModaﬁnilþRitalinþIRSSþAnticonvulsant 1 1 0.82
ModaﬁnilþTricyclic 1 1 0.82
ModaﬁnilþAnticonvulsant 1 1 0.82
ModaﬁnilþRitalinþTricyclicþIRSS 1 1 0.82
ModaﬁnilþRitalinþIRSSþSNRIsb 1 1 0.82 19.38
Other medications but not modaﬁnil 22 24 13 12 71 58.20 58.20
No prescribed medication 5 5 4 2 16 13.11 13.11
Total 34 39 27 22 122 100 100
a Serotonin-reuptake inhibitor.
b Serotonin and noradrenalin-reuptake inhibitor.
Table 2 – Motives for discontinuation of the use of
modaﬁnil (some of them are over layered in the same
patient).
Number of cases Frequency
(%)
Side effects 9 36
Poor clinical
improvement
5 20
No speciﬁed motive 5 20
High cost 4 16
Pregnancy 1 4
Bariatric surgery pre op 1 4
Total 25 100
Table 3 – Frequency of side effects on several patients.
Patients
Headache 3
Diarrhea, nausea and leg pain 1
Tingling in legs 1
Sleepiness, increase in hallucinations and acne 1
Important memory loss 1
Abortion 1
Non speciﬁed discomfort 1
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be taken based on clinical criteria, the safety of the treatment
with sympathomimetic drugs, or the associated risks for
every patient. In parallel, the association of drugs for the
control of cataplexy must be evaluated in these cases [7–10].
In any case and independently of the pharmacological
treatment of choice, there must be a regular patient follow up
to verify the side effects, including sleep disturbances, humor
changes, methabolic and cardiovascular abnormalities. This
way, this follow up is also important to determine treatmentadherence and treatment response, monitor drug safety and
be prepared to solve any social or occupational hazard that
might appear during the course of treatment, when the
symptoms of narcolepsy are not well controlled [8–10].
The choice for the treatment with modaﬁnil must be done
after a precise indication for the control of DES. Even though
with the signiﬁcant improvements on the understanding of
narcolepsy's physiopathology, there is still no treatment that
completely recovers and maintains awareness during the
entire day [7,8]. In this context, initial and progressive doses
and constant monitoring are essential, even though, moda-
ﬁnil is the drug with the safest proﬁle compared to others.
The regular follow up of the patient facilitates the identiﬁca-
tion of early complications with the discontinuation of
modaﬁnil, if necessary and the evaluation of the clinical
response seems to be the correct way to manage the therapy.5. Conclusions(1) This study demonstrates the safety of the use of modaﬁnil
for the treatment of DES in patients with narcolepsy
attended by our specialized center.(2) Side effects as headache, anxiety, nausea, dry mouth,
diarrhea, asthenia and insomnia are reversible after dis-
continuation of the drug.(3) The medication should have been included in the list of
free medications available to the general public due to its
high cost and good results for these patients.
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